Khan, Mohid  ORCID: https://orcid.org/0000-0002-1272-241X, Cook, Kathryn, Weickert, Martin O ORCID: https://orcid.org/0000-0002-4070-8164, Davies, Louise, Pritchard, D. Mark ORCID: https://orcid.org/0000-0001-7971-3561, Day, Melissa, Shah, Tahir ORCID: https://orcid.org/0000-0002-0420-0304, Hull, Diana ORCID: https://orcid.org/0000-0002-0425-541X, Caplin, Martyn ORCID: https://orcid.org/0000-0003-0177-1352, Back, Melissa ORCID: https://orcid.org/0009-0007-4430-6289, Pommie, Christelle ORCID: https://orcid.org/0009-0001-8771-2304 and Higgs, Kate
2024.
PREF‐NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK.
Supportive Care in Cancer
32
, 199.
10.1007/s00520-024-08377-7
|
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (1MB) | Preview |
Abstract
Purpose: PREF-NET reported patients’ experience of Somatuline® (lanreotide) Autogel® (LAN) administration at home and in hospital among patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Methods: PREF-NET was a multicentre, cross-sectional study of UK adults (aged ≥ 18 years) with GEP-NETs receiving a stable dose of LAN, which comprised of (1) a quantitative online survey, and (2) qualitative semi-structured interviews conducted with a subgroup of survey respondents. The primary objective was the description of overall patient preference for home versus hospital administration of LAN. Secondary objectives included describing patient-reported opinions on the experience and associated preference for each administration setting, and the impact on healthcare utilisation, societal cost, activities of daily living and health-related quality of life (HRQoL). Results: In the primary analysis (80 patients; mean age 63.9 years), 98.7% (95% confidence interval [CI]: 96.1–100.0) of patients preferred to receive LAN at home, compared with 1.3% (95% CI: 0.0–3.9) who preferred the hospital setting. Among participants, over half (60.3%) received their injection from a non-healthcare professional. Most patients (79.5% [95% CI: 70.5–88.4]) reported a positive effect on HRQoL after the switch from hospital to home administration. Qualitative interviews (20 patients; mean age 63.6 years) highlighted that patients preferred home administration because it improved overall convenience; saved time and costs; made them feel more comfortable and relaxed, and less stressed; and increased confidence in their ability to self-manage their treatment. Conclusion: Almost all patients preferred to receive LAN treatment at home rather than in hospital with increased convenience and psychological benefits reported as key reasons for this preference.
| Item Type: | Article |
|---|---|
| Date Type: | Published Online |
| Status: | Published |
| Schools: | Schools > Medicine Research Institutes & Centres > Wales Cancer Research Centre (WCRC) |
| Publisher: | Springer Nature |
| ISSN: | 0941-4355 |
| Date of First Compliant Deposit: | 4 March 2024 |
| Date of Acceptance: | 12 February 2024 |
| Last Modified: | 06 Mar 2024 11:57 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/166857 |
Actions (repository staff only)
 |
Edit Item |
Dimensions
Dimensions
Cardiff University Information Services